Harbor Capital Advisors Inc. reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 39.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,683 shares of the medical device company’s stock after selling 1,718 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in DexCom were worth $209,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of DXCM. Versant Capital Management Inc purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $25,000. Riverview Trust Co lifted its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the 3rd quarter valued at $57,000. Covestor Ltd increased its holdings in shares of DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of DexCom by 101.9% in the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after purchasing an additional 898 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.
DexCom Trading Down 0.8 %
Shares of NASDAQ:DXCM opened at $79.17 on Wednesday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a market cap of $30.92 billion, a PE ratio of 47.41, a price-to-earnings-growth ratio of 2.36 and a beta of 1.12. The stock has a 50 day moving average of $77.33 and a 200 day moving average of $78.35. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.
Insiders Place Their Bets
Wall Street Analyst Weigh In
Several research firms recently commented on DXCM. Wells Fargo & Company increased their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Citigroup raised their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Canaccord Genuity Group increased their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.00.
Get Our Latest Stock Analysis on DXCM
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Recommended Stories
- Five stocks we like better than DexCom
- What is the S&P/TSX Index?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Financial Services Stocks Investing
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.